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Abstract: Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia.
The availability of new antidiabetic drugs (ADs) has led to complex treatment patterns and to
changes in the patterns of specific drug utilization. The aim of this population-based study was
to describe the pattern of antidiabetic drugs (ADs) use in Southern Italy in the years 2011–2017,
in relation to the updated type 2 diabetes mellitus (T2DM) therapy guidelines. A retrospective cohort
study was conducted on T2DM patients using data from the Palermo Local Health Unit (LHU)
claims database and diabetologist registry. The first-line treatment was investigated and incident
treatments were identified and characterized at baseline in terms of demographics, complications,
comorbidities, concomitant drugs and clinical parameters. Persistence to AD treatment was also
evaluated. During the study period, one-third of first ever ADs users started the treatment with
ADs other than metformin, in contrast to guideline recommendations. Among 151,711 incident AD
treatments, the male to female ratio was 1.0 and the median age was 66 (57–75) years. More than
half (55.0%) of incident treatments discontinued the therapy during the first year of treatment.
In Italy, general practitioners (GPs) can only prescribe first-generation ADs, while the prescription of
more recently marketed ADs, such as GLP-1RA, DPP4i and SGLT2i, is restricted to diabetologists
only, based on a therapeutic plan. The role of GPs in the management of T2DM in Italy should
be re-evaluated.
Keywords: antidiabetic drugs; real world data; type 2 diabetes mellitus; therapy guidelines;
Southern Italy
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1. Introduction
Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia as a consequence
of defects in insulin action, secretion, or both. Diabetes currently affects more than 425 million people
over the world, and the number of patients with diabetes is estimated to rise up to 693 million in
2045 [1]. In Europe, 58 million people are affected by diabetes, despite 22 million of these being
undiagnosed cases [1]. In Italy, type 2 diabetes (T2DM) accounts for over 90% of diabetes cases, with a
prevalence of about 5% [2] in the general population, which further increases in Southern Italian
Regions [3]. Specifically, Sicily is among the Italian regions with the largest consumption (around
80 Defined Daily Dose (DDD)/1000 inhabitants/day) of antidiabetic drugs (ADs) [4,5].
The growing number of people with T2DM has a great impact not only in terms of clinical effects,
but also in terms of economic burden on the healthcare systems [6]. T2DM is a major risk factor for
cardiovascular (CV) diseases, such as stroke, myocardial infarction and peripheral vascular disease,
as well as being an independent risk factor for heart failure [7,8]. In patients with diabetes mellitus, CV
complications are considered the main cause of morbidity and mortality [9,10]. As mentioned in the
2019 ESC guidelines, the early identification and treatment of comorbidities and factors that increase
CV risk can bring great benefits to patients with glucose perturbations [11].
According to the 2012, 2015 and 2018 guidelines of the American Diabetes Association (ADA) and
the European Association for the Study of Diabetes (EASD) on the management of hyperglycemia in
T2DM, metformin is recommended as a first-line glucose-lowering therapy, if well-tolerated, in addition
to lifestyle changes [8,12,13]. When glycemic control is not reached with metformin monotherapy
at the maximum tolerated dose, adding a second AD is recommended. In particular, before 2018,
the guidelines recommended the prescription of a two-drugs combination, choosing the AD to be
added to metformin on the basis of several patient- and disease-specific factors. If glycemic control
was not reached within three months of dual therapy, adding another AD (triple therapy) was
recommended. Combination with injectable therapy (metformin + insulin + mealtime insulin or
glucagon-like peptide-1 receptor agonists (GLP-1RA)) was recommended when glycemic control was
not achieved within 3 months of triple therapy [12,13].
On the contrary, the last updated EASD-ADA guidelines recommend either GLP-1RA or
sodium–glucose linked transporter 2 inhibitor (SGLT2i) as the second-line treatment in patients
affected by established atherosclerotic cardiovascular disease (ASCVD), heart failure or chronic kidney
disease (CKD), or in those in which a minimization of weight gain is necessary [8]. In patients without
established ASCVD or CKD, if there is a need to minimize hypoglycemia risk, dipeptidyl peptidase-4
inhibitors (DPP4i), GLP-1RA, SGLT2i or glitazones should be added to metformin; finally, only if
affordability is a major issue, sulfonylureas or glitazones should be added to metformin. When glycemic
control is not achieved with the oral ADs, the previous and the new EASD-ADA guidelines recommend
the addition of or the switch to insulin therapy [8,13].
Nevertheless, in Italy, general practitioners (GPs), who play a major role in T2DM management,
can only prescribe first-generation ADs, such as metformin, sulfonylureas, glinides, acarbose and
glitazones, while the prescription of more recently marketed ADs, such as GLP-1RA, DPP4i and
SGLT2i, is restricted to diabetologist only, based on a therapeutic plan [2].
The objective of this population-based study was to explore the real-world use of ADs in a large
province of Southern Italy in the years 2011–2017, in relation to recently updated guidelines.
2. Materials and Methods
2.1. Data Source and Study Design
An observational, retrospective study was conducted from 2011 to 2017 in collaboration with the
Sicilian Regional Department for Health Activities and Epidemiological Observatory, the Palermo
Local Health Unit (LHU) and the Regional Center of Reference Diabetology and Microinfusion Plant
Sicily—Civic Hospital of Partinico (Province of Palermo). Altogether, these centers provided access to
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fully anonymized data from the claims database and diabetologist registry of Palermo LHU (covering
a total population of 1,362,708 people during the study years). As not all T2DM patients were cared for
by diabetologists, clinical data from registries were available only for a subsample of the study cohort.
The claims database included information on demographics of residents, outpatient pharmacy claims
(drug dispensing data), hospital discharges, emergency department (ED) visits and healthcare service
payment exemptions.
The diabetologist registry included information on the antidiabetic prescriptions, history of
diabetes-related complications and clinical parameters (e.g., glycated hemoglobin, cholesterol,
triglycerides, transaminases, albumin extraction rate, creatinine clearance, body mass index (BMI),
body weight, waist circumference). The dispensed drugs were coded using the Anatomical Therapeutic
Clinical (ATC) classification system and the Marketing Authorization Code (AIC), while comorbidities
and complications were coded through the ninth review of the International Classification of
Diseases—Clinical Modification (ICD9-CM).
The study protocol was notified to the Ethical Committee of the Academic Hospital of Messina
(Prot. N. 0001373 of the 01/24/2018), according to the current national law [14]. The manuscript does
not contain clinical studies or patient data. For this type of study formal consent is not required.
2.2. Study Population
From the general population of Palermo LHU, all subjects with at least one year of database
history and at least one AD dispensed (i.e., prevalent users) during the years 2011–2017 were identified.
Of these, all AD users without any dispensing of the same AD in the year prior to the ID (i.e., incident
AD users) were then identified. The index date was defined as the date of the first AD dispensing
during the study period. The same patient could be included in several AD classes (i.e., incident AD
treatment), and multiple index dates (one for each AD that was initiated during follow-up) for the
same patient were allowed. All AD users with a diagnosis of T1DM (identified from diabetologist
registry and/or from discharge diagnosis database), or with ages less than 20 years and exclusive
treatment with insulin, or gestational diabetes or other types of non-T2DM, were excluded.
2.3. Study Drugs
All the marketed molecules/classes of ADs included in the study and their ATC codes are listed in
Table A1. Specifically, in light of the change of some drug ATCs in 2017, the previous ATCs of these
drugs were included as well ((exenatide (A10BX04); liraglutide (A10BX07); lixisenatide (A10BX10);
albiglutide (A10BX13); dulaglutide (A10BX14), dapagliflozin (A10BX09); canagliflozin (A10BX11);
empagliflozin (A10BX12)) [15].
All available AD dispensing data were identified from the Palermo claims database.
2.4. Data Analysis
First, the distribution of the dispensed ADs as first-line treatment was investigated. Only subjects
not treated with ADs before the first AD dispensing during the study period (first ever users) were
included in this analysis. Second, the prevalence (%) of AD users, stratified by calendar year and AD
molecule/class, was also evaluated. Third, among incident treatments, the distribution of previous
use of other ADs (i.e., at least one dispensing any time prior to ID) was evaluated and stratified
by molecule/class.
Then, a baseline characterization of incident treatments, stratified by antidiabetic drug/class,
was performed. The variables examined included patients’ demographics, comorbidities, DM
complications, concomitant drugs and clinical parameters (Table A2).
All incident AD treatments with at least 180 days of follow-up and at least one HbA1c measurement
within 1 month prior to the ID (i.e., baseline HbA1c value), and another one within the 6th month after
ID (follow-up HbA1c), were identified. The difference between the mean follow-up and the baseline
HbA1c values, i.e., delta Hb (∆HbA1c), was calculated and stratified by AD molecule/class.
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The same analysis for waist circumference and body weight measurement was performed by
comparing values at baseline vs. those measured within 12 months after ID.
Among incident AD treatments, time to discontinuation analysis during the first year of treatment
was carried out. For each incident AD treatment, the number of days of continuous therapy from the
treatment’s start, based on the DDD and the amount of dispensed ADs, was estimated. Concerning
fixed-dose combinations, as DDD does not exist, we assumed that patients received one tablet a day.
Persistence to AD treatment was assessed based on the maximum allowed treatment gap, defined as
the time between the last day covered by AD treatment (discontinuation date) and the day to the next
refill. Patients were considered discontinuers if they had at least one treatment gap exceeding 90 days
between the estimated end of exposure of the last drug dispensing and the start of the next one (if any).
For discontinuers, the time to discontinuation was calculated as the number of days between ID and the
discontinuation date. Antidiabetic drug/class-specific time to discontinuation analysis was performed
using a Kaplan–Meier plot. Persistence to insulin was not evaluated since no standard duration of
treatment with insulin exists because the actual administered daily doses may vary substantially
depending on the health conditions of the patient; therefore, in general, the assessment of adherence
and persistence to insulin treatment using claims databases may not be accurate.
Then, discontinuers were re-classified as intermittent users if they received at least one dispensing
of the same AD between the discontinuation date and the end of the first year of follow-up. Instead,
continuers were re-classified as add-on users if they received at least one additional AD (never prescribed
before) between the ID and the end of the first year of follow-up.
All the analyses on drug utilization were carried out only using the claims database covering the
whole T2DM population.
Descriptive statistics were used to describe all examined variables. The results are presented
as mean ± standard deviation (SD) or median with interquartile range (IQR) depending on the
underlying distribution for quantitative variables, and they were summarized by absolute frequencies
and percentages for categorical variables.
In order to compare proportions and variations (as %) between the different groups, a Generalized
Estimating Equations (GEE) model was fitted, using a binomial and Gaussian link function for
binary and continuous variables, respectively. For comparisons within groups, a paired t-test was
used. Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA). Generalized
Estimating Equations models were performed in R version 3.5.0 using the geepack package (version
1.3-1). The significance level for all statistical tests was set at p-value < 0.05.
3. Results
During the study period, from a population of about 1.4 million patients registered in Palermo LHU,
excluding 2797 patients with T1DM, gestational diabetes or other types of non-T2DM, 151,744 incident
T2DM AD treatments were identified. Clinical data from the diabetologist registry were available for a
subsample of 48,498 (32.0%) incident AD treatments (Figure 1).
The overall prevalence (%) of AD users was 9.1%, with a stable trend during the study years.
However, a slight decrease in metformin + sulfonylureas fixed-dose combination use was observed
over time (from 0.6% in 2011 to 0.2% in 2017). On the contrary, a slight increase in the more recently
marketed SGLT2i and metformin + SGLT2i fixed-dose combination from 2015 onwards was found.
The use of the other first-generation ADs remained almost steady during the study period (Figure A1).
During the observation years, among the 44,692 subjects that were the first ever users of ADs,
only two-thirds (N = 29,514; 66.0%) received metformin as the first-line treatment, with the remaining
ones mostly receiving insulin (N = 3807; 8.5%) and first-generation ADs, such as sulfonylureas
(N = 3638; 8.1%), glinides (N = 2428; 5.4%) and AGIs (N = 2083; 4.7%) (Figure 2).
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Figure 1. Flow-chart of T2DM patients receiving antidiabetic drugs in Palermo Local Health Unit
in the years 2011–2017. Legend: LHU: Local Health Unit; AD: Antidiabetic drug; T1DM: Type 1
diabetes mellitus; T2DM: Type 2 diabetes mellitus. a Subjects without any AD dispensing of the same
drug within one year prior to the treatment start date, i.e., index date (ID). The same patient could be
included in different AD classes; for this reason, incident T2DM AD treatments were more numerous
than prevalent users.
Figure 2. Distribution (%) of the first antidiabetic drug use, stratified by antidiabetic
molecule/class. Legend: AGI = alpha-glucosidase inhibitors; DPP4i = dipeptidyl peptidase-4
inhibitors; GLP-1RA = glucagon-like peptide-1 receptor antagonists; SGLT2i = sodium–glucose
linked transporter 2 inhibitors; Other oral combinations = fixed-dose combinations of glitazones +
DPP4i and glitazones + sulfonylureas.
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Non fixed-dose combinations include AD users with more than one AD dispensing at the
index date.
Only AD users not treated with any AD before the first dispensing date during the study period
were included in this analysis.
Looking at the previous use of ADs, 1581 (37%) and 1769 (61%) patients with GLP1-RA and
SGLT2i incident treatments, respectively, had received more than three other ADs before GLP1-RA and
SGLT2i were started (Figure 3).
Figure 3. Distribution (%) of the number of ADs dispensed any time prior to the treatment start among
incident treatments. Legend: AGI = alpha-glucosidase inhibitors; DPP4i = dipeptidyl peptidase-4
inhibitors; GLP-1RA = glucagon-like peptide-1 receptor antagonists; SGLT2i = sodium–glucose linked
transporter 2 inhibitors; Other oral combinations = fixed-dose combinations of glitazones + DPP4i and
glitazones + sulfonylureas. Only number of ATCs belonging to a different antidiabetic molecule/class
as compared to the molecule/class that was dispensed at the index date.
In general, among all incident AD treatments, a male to female ratio of 1.0 was observed, except
for incident treatments of metformin + SGLT2i, metformin + glitazones and other oral antidiabetic
fixed-dose combinations (male to female ratio = 1.4); the overall median age was 66 (IQR: 57–75)
years, except for those undergoing incident treatments of SGLT2i, GLP-1RA, and metformin + SGLT2i
fixed-dose combinations, who were significantly younger (i.e., 56 years) (p-value < 0.05) (Table 1).
Only a very low proportion of incident treatments of SGLT2i and GLP1-RA had a history of heart
failure or nephropathy, compared to incident treatments of glinides and insulin (heart failure: 5.1%
and 5.9% vs. 10.2% and 11.6%, respectively (p-values < 0.001 for both comparisons); nephropathy:
7.7% and 7.4% vs. 11.2% and 12.4%, respectively (p-values < 0.001 for both comparisons)).
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Legend: AGI = alpha-glucosidase inhibitors; DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA = glucagon-like peptide-1 receptor antagonists; SGLT2i = sodium–glucose linked
transporter 2 inhibitors; SU = sulfonylureas; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; ID = index date; IQR = interquartile range. The other oral
combinations include fixed-dose combinations of glitazones + DPP4i and glitazones + sulfonylureas. a Evaluated any time prior to ID and identified looking at ICD9-CM codes from
discharge diagnosis database or codes from exemptions from healthcare service co-payment database. b Dementia, hypertension, lipid metabolism disorders and gout were identified by
looking at ICD9-CM codes from the discharge diagnosis database, or codes from exemptions from the healthcare service co-payment database or the specific ATC codes from the outpatient
drug dispensing database. c This category includes: angina pectoris, ischemic heart disease, acute myocardial infarction. d This category includes: transient cerebral ischemia and stroke.
e Evaluated any time prior to ID and identified by looking at ICD-9 codes from discharge diagnosis database or diabetologist registry or codes from exemptions from the healthcare
service co-payment database. f Evaluated within three months prior to ID and identified by looking at ATC codes from outpatient drug dispensing. g This category includes: vitamin
K antagonists, heparins, thrombin direct inhibitors, factor Xa direct inhibitors, fibrinolytic agents. h This category includes: platelet aggregation inhibitors. i This category includes:
Pregabalin, Gabapentin and Duloxetin.
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History of heart failure was observed in 4.3% of incident treatments of glitazones. Hypertension
and lipid metabolism disorders were the most common comorbidities (76.6% and 50.7%, respectively),
and proton pump inhibitors (55.5%) were the most frequently used concomitant drugs.
Among incident treatments of ADs with available clinical parameters from the diabetologist
registry, the baseline HbA1c values were always over the target range, with the highest values being
reported for incident treatments of SGLT2i (N = 1221 (79.6%); median (IQR): 8.9% (7.9–9.9%)), insulin
(N = 3845 (47.6%); median (IQR): 8.8% (7.7–10.2%)) and a fixed-dose combination of metformin
+ sulfonylureas (N = 463 (48.2%); median (IQR): 8.7% (7.6–10.0%)) (p-value < 0.05) (Table 2).
Within 6 months after ID, the variation (%) in HbA1c values was more marked among incident
treatments of fixed-dose combination of metformin + SGLT2i (−15.7%), SGLT2i (−12.8%) and insulin
(−12.7%), as compared to other AD classes (p-values < 0.001) (Figure 4).
All incident AD treatments within at least 6 months of follow-up, with at least 1 HbA1c
measurement at baseline and within 6 months from baseline, were included.
The highest baseline body weight as well as waist circumference values were observed among
incident treatments of newly marketed ADs, such as GLP1-RA (N = 1127 (59.0%); median (IQR)
body weight: 95.0 kg (84.0–107.5 kg); N = 569 (29.8%), median (IQR) waist circumference: 116.0 cm
(108.0–123.0 cm)) and fixed-dose combinations of metformin + SGLT2i (N = 438 (79.5%); median (IQR)
body weight: 89.0 kg (79.0–102.0 kg); N = 295 (53.5%), median (IQR) waist circumference: 115.0 cm
(106.0–120.0 cm)) and SGLT2i (N = 1231 (80.3%); median (IQR) body weight: 87.7 kg (77.5–100.4 kg);
N = 669 (43.6%), median (IQR) waist circumference: 112.0 cm (104.0–120.0 cm)) (p-values < 0.05)
as compared with other AD groups (Table 2). Statistically significant changes in body weight and
waist circumference values within one year after ID were observed (Figures A2 and A3). Specifically,
the reduction in body weight values was more marked among incident treatments of fixed-dose
combination of metformin+SGLT2i (−2.4%), SGLT2i (−1.7%) and GLP1-RA (−1.6%) (p-values < 0.001)
as compared with other AD groups. Additionally, for waist circumference, the reduction in mean
values was more marked among incident treatments of fixed-dose combinations of metformin+SGLT2i
(2.1%) and GLP1-RA (−1.6%;) (p-values < 0.001).
During the first year of AD treatment, more than half (55.0%) of the 106,484 incident AD treatments
included in the persistence analysis discontinued the treatment, with the highest proportions of
discontinuers being observed among incident treatments of the metformin + sulfonylureas fixed-dose
combination (65.9%) and AGIs (62.2%) (p-value < 0.05). Moreover, 52.3% of sulfonylureas users
discontinued during the first year of treatment. One-fourth of incident treatments received only
one dispensing of AD (i.e., occasional users) during the first year of treatment. On the contrary,
the proportion of discontinuers was lower among incident treatments of more recently marketed
ADs, such as GLP1-RA and fixed-dose combinations of metformin+SGLT2i and metformin + DPP4i
(p-values < 0.05 for comparison with other AD groups) (Figure 5).
Overall, within the first year of treatment, 13.9% of incident AD treatments were intermittent
users, as the same AD treatment was restarted after discontinuation. The highest percentages of
intermittent users were found among metformin users (17.7%) (p-value < 0.05). Overall, 20,389 (19.1%)
incident AD treatments received an add-on therapy during the first year of treatment, mostly among
incident treatments of metformin (29.5%) (Figure A4).
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Legend: AGI = alpha-glucosidase inhibitors; DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA = glucagon-like peptide-1 receptor antagonists; SGLT2i = sodium–glucose linked
transporter 2 inhibitors; SU = sulfonylureas; DM = diabetes mellitus; IQR = interquartile range; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamate-pyruvate
transaminase; BMI = body mass index. The other oral combinations include fixed-dose combinations of glitazones + DPP4i and glitazones + sulfonylureas. * In subjects ≤ 70 years old,
glycated hemoglobin target value < 7%; in subjects 70 years old, glycated hemoglobin target value ≤ 8%.
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Figure 4. Comparison between the mean HbA1c values (%) at baseline and within six
months after ID, stratified by AD molecule/class. Legend: AGI = alpha-glucosidase inhibitors;
DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA = glucagon-like peptide-1 receptor antagonists;
SGLT2i = sodium–glucose linked transporter 2 inhibitors; Other oral combinations = fixed-dose
combinations of glitazones + DPP4i and glitazones + sulfonylureas; ID = index date. In subjects ≤ 70 years
old, glycated hemoglobin target value < 7%; in subjects > 70 years old, glycated hemoglobin target
value ≤ 8%.
Figure 5. Time to discontinuation of AD treatment during the first year among incident
treatments, stratified by antidiabetic molecule/class. Legend: AGI = alpha-glucosidase inhibitors;
DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA = glucagon-like peptide-1 receptor antagonists;
SGLT2i = sodium–glucose linked transporter 2 inhibitors; Other oral combinations = fixed-dose
combinations of glitazones + DPP4i and glitazones + sulfonylureas.
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4. Discussion
This population-based study investigated the prescribing pattern of ADs in a large province of
Southern Italy, which has one of the highest T2DM prevalence rates in Italy. Our results showed that
only two-thirds of T2DM patients received metformin as the first-line treatment, in line with guidelines.
Around 10% of T2DM patients received as the first-line treatment insulin, which may be appropriate
only in cases of marked glycometabolic decompensation or CKD [16]. In particular, in 3–5 CKD stage
patients, insulin therapy is appropriate with proper dosage reduction [17].
Instead, more than 20% of T2DM patients were treated with other non-metformin first-generation
ADs, such as sulfonylureas, glinides and AGIs, which is in contrast with the updated guidelines unless
the use of metformin was not tolerated or contraindicated (e.g., severe renal impairment, that is, CKD
stage ≥4). An exploratory analysis showed that among the 336 patients starting the treatment with
ADs different from metformin and for which information of the CKD stage was available, 137 (40.8%)
subjects had a diagnosis of severe renal impairment (e.g., CKD stage IV–V or dialysis) and were
therefore not eligible for the treatment with metformin. However, 11% of incident treatments of
glinides had a history of nephropathy; despite the fact that in this clinical condition updated guidelines
suggest using SGLT2i or GLP-1RA, glinides are considered safe in advanced renal disease with cautious
dosing [8].
Concerning glitazones, our results showed that a relatively low proportion of glitazones users had
a history of heart failure despite the fact that they are significantly and consistently associated with a
high risk of heart failure [18], and therefore they are not recommended in patients with established
New York Heart Association (NYHA) III/IV heart failure [19].
Due to hypoglycemia risk, current treatment guidelines recommend sulfonylureas only as a
third-line treatment, and this is mostly driven by affordability issues. However, a population-based
study conducted in Ireland in 2015 [20,21] showed that sulfonylureas were used as first-line treatment
in 22% of T2DM patients. In another population-based study conducted in Catalonia in 2016 [22],
the authors noted an increase in the use of metformin and a decrease in the use of sulfonylureas
from 2007 to 2013, and similar results were found in other population-based studies [23–26]. Finally,
the wide use of sulfonylureas and other non-metformin first-generation ADs as observed in our study
may be due to the fact that most of the T2DM patients are cared for by GPs only, who are allowed to
prescribe only those low-cost ADs.
Moreover, our results showed that users of GLP-1RA or SGLT2i, which are recommended
as second-line treatments according to updated guidelines, received four other ADs belonging to
different pharmacological classes, as an add-on or switch, before starting treatment with these drugs.
Furthermore, these pictures have to be carefully interpreted as updated guidelines recommending the
use of SGLT2i as a second-line treatment were published in 2018, while those drugs were marketed only
in April 2015 in Italy, thus limiting the assessment of patterns of SGLT2i use in our study. Moreover,
our results show that the highest baseline median HbA1c values were reported for incident SGLT2i
treatments. Accordingly, the SGLT2i class was the only class among ADs recently marketed that could
be prescribed by specialists in Italy without any restriction based on HbA1c values, while GLP1-RA
could be prescribed only to patients with HbA1c values between 7.5% and 8.5% [8]. Moreover,
within the first six months of therapy, the reduction in HbA1c values was more marked among incident
treatments of insulin, SGLT2i and fixed-dose combinations of metformin + SGLT2i than other ADs.
This was in line with a meta-analysis conducted by Storgaard et al., showing that SGLT2is, at the
recommended daily target doses, were associated with a larger reduction in HbA1c levels in patients
with T2DM as compared with other existing oral ADs, especially sulfonylureas and DPP4i [27]. This is
especially true when SGLT2is are used in combination with metformin, due to the complementary
effects of these drugs, which have different mechanisms of actions [28]. It is known that insulin is
the most effective AD for reducing HbA1c levels, and its main advantage is that the HbA1c level’s
reduction is dose-dependent [29].
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As expected, the highest baseline body weight values, as well as waist circumference values,
were observed among incident treatments of more recently marketed ADs, such as GLP1-RA, SGLT2i
and fixed-dose combinations of metformin + SGLT2i. This is in line with guidelines, which recommend
the prescription of these ADs in patients prioritizing weight loss or weight maintenance [8].
In general, discontinuation may result from intolerance or side-effects, and our results showed
that during the first year of treatment, more than half of the patients with incident treatments of
ADs, especially AGIs and fixed-dose combinations of metformin + sulfonylureas, discontinued the
therapy. This finding is in line with other national/international population-based studies, showing
that up to 50% of T2DM patients discontinued AD treatment during the first year of therapy [30,31].
AD treatment discontinuation in the elderly population could be explained by the need to avoid
hypoglycemic events that can be fatal in fragile patients; that is why higher glycated hemoglobin
levels are allowed in elderly patients [32]. Concerning AGIs, discontinuation was probably due to
their known gastrointestinal effects [8,33]. The high proportion of discontinuers among sulfonylureas
users as well as users of fixed-dose combinations of metformin + sulfonylureas could be explained by
the high risk of symptomatic hypoglycemic events [34]. AD treatment discontinuation is associated
with a worsening of glucose metabolism, and therefore with increased glycated hemoglobin values
that could determine a series of consequences related to macroangiopathy, microangiopathy and
diabetic neuropathy [35]. Such consequences may lead to an increased cardiovascular risk and clinical
complications that can negatively impact the NHS.
In our study, 25% of the incident treatments were occasional (only one AD dispensing), especially
among AGIs and metformin groups (data not shown). However, the proportion of metformin
occasional users could probably be overestimated. In Italy, metformin is very cheap and, according
to the “IMS-Health Italy” database, which provides aggregated data on drugs dispensed by private
pharmacies and distinguishes between dispensing reimbursed and not reimbursed (e.g., paid directly
by patients) by the National Health System, around 20% of metformin is purchased outside the
National health Service (NHS), hence not being fully traceable using claims databases. In addition,
almost one-third of incident treatments of metformin received an add-on therapy during the first year
of treatment, probably because glycemic control was not achieved with metformin monotherapy.
On the contrary, lower proportions of discontinuers were observed among incident treatments of
more recently marketed ADs, such as GLP1-RA, DPP4 and metformin+DPP4i, which are generally
well tolerated, and are associated with weight loss and low risk of hypoglycemia [36]. Moreover,
patients treated with these ADs are cared for by diabetologist (as GPs cannot prescribe those drugs),
who can be more effective in motivating patients to continue AD treatment, especially as periodic visits
are planned to assess therapy and eventually renew therapeutic plans.
Strengths and Limitations
The main strengths of this study are the large size of the study cohort and the availability of the
claims plus diabetologist registry from the same catchment area for a period of 8 years.
On the other hand, some study limitations warrant caution. First, clinical data from the
diabetologist registry were limited to a low sample of the study cohort with likely more advanced or
complicated diabetes mellitus. In Italy, only the diabetologist may prescribe more recently marketed
ADs, such as GLP-1RA, DPP4i and SGLT2i, while GPs can prescribe only first-generation ADs [37].
Second, the persistence to treatment was assessed on the basis of DDD for non-fixed dose
combinations, but clearly situations in which some patients have to intensify the therapy could occur,
and therefore DDD could not reflect the doses used in the real world. This is the case of insulin:
as no standard duration exists because it depends on the health condition of the patient, insulin was
excluded from the persistence analysis (Figure 5) and from the analysis of the distribution of continuers,
add-on, discontinuers and intermittent users (Figure A4). Moreover, the doses of sulfonylureas, usually
prescribed by GPs, are substantially variable (from half to three tablets a day, as specified in the summary
of product characteristics). For this reason, we cannot rule out that persistence to sulfonylureas may be
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partly underestimated. However, the proportion of discontinuers among users of sulfonylureas was
not significantly higher than discontinuers of other Ads, and it is well known that the hypoglycemic
effects of sulfonylureas may trigger discontinuation. Concerning fixed-dose combinations, as a DDD
does not exist, we assumed that the dosing regimen was one tablet a day. However, in the case of
fixed-dose combination of metformin + sulfonylureas, the dose, again, is related to patient tolerance or
the patient’s renal function. For this reason, discontinuation could be overestimated.
Third, not all AD dispensing can be completely traced, as 16% of ADs dispensed in Palermo
LHU were reported as being purchased outside the NHS during the study years, with the highest
percentages for lowest-costing Ads, such as metformin (cost = EUR 3.00; estimated purchase outside
the NHS = 20%). However, in Italy, it is unlikely that a patient after receiving a diagnosis of diabetes
mellitus and a first AD prescription by the GP/diabetologist will purchase a drug outside the NHS in
private pharmacy, without any reimbursement, and consequently the first AD dispensing is missing.
As such, it is highly unlikely that the first AD drug dispensing goes untraced. However, this could at
least partly explain the very high proportion of intermittent users/discontinuers that could directly
purchase a low-cost AD in a private pharmacy without receiving the prescription from the GP/specialist.
Finally, our findings cannot be fully generalized to the whole Italian general population, as the
study was restricted to a LHU of Southern Italy.
5. Conclusions
In a general population from Southern Italy, a large use of non-metformin first-generation ADs,
as both first- and second-line treatments and with high short-term discontinuation rates, was observed.
This is likely due to the fact that about 70% of T2DM patients in the Palermo LHU were cared for only
by GPs, who may prescribe only first-generation ADs, despite updated guidelines recommending
as second-line therapies more recent and higher-cost drugs, such as DPP4i, GLP1-RA and SGLT2i.
A linkage of claims databases with clinical registries can help rapidly explore the effectiveness and
safety issues in real-world settings. In the near future, further analyses re-evaluating the pattern
of recently marketed antidiabetic drugs in relation to the updated type 2 diabetes mellitus therapy
guidelines, as well as the role of GPs in the prescription of more recently marketed ADs in Italy, need to
be performed. It is also crucial to establish an alliance between physicians and patients aimed at
implementing treatment adherence by increasing patient’s knowledge of the possible complications that
chronic diseases such as diabetes can cause. New strategies, such as lifestyle modifications, reductions
in the major risk factors (e.g., obesity, physical activity, tobacco smoking, alcohol consumption and
mental stress) responsible for T2DM, and other educational programs for both physicians and patients,
are needed to prevent and/or delay the onset of diabetes and to promote AD therapy adherence in
order to avoid, or reduce as much as possible, treatment-related adverse events. This would result in
significant reductions in social burden and economic costs.
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Appendix A
Table A1. List of study drugs.
Molecule/Class ATC Codes
Metformin A10BA02
DPP4i A10BH01, A10BH02, A10BH03, A10BH04, A10BH05
SGLT2i A10BK01, A10BK02, A10BK03, A10BX09, A10BX11, A10BX12




Insulin A10AB.xx, A10AC.xx, A10AD.xx, A10AE01, A10AE04, A10AE05, A10AE06
Sulfonylureas A10BB.xx
Fixed-dose combinations
Metformin + DPP4i A10BD07, A10BD08, A10BD10, A10BD11, A10BD13
Metformin + SGLT2i A10BD15, A10BD16, A10BD20
Metformin + glitazones A10BD03, A10BD05
Metformin + sulfonylureas A10BD01, A10BD02
Other oral combinations A10BD09, A10BD04, A10BD06
Legend: ATC = anatomical therapeutic clinical; AGI = alpha-glucosidase inhibitors; DPP4i = dipeptidyl peptidase-4
inhibitors; GLP-1RA = glucagon-like peptide-1 receptor antagonists; SGLT2i = sodium–glucose linked transporter 2
inhibitors; Other oral combinations = fixed-dose combinations of glitazones + DPP4i and glitazones + sulfonylureas.
Int. J. Environ. Res. Public Health 2020, 17, 9514 16 of 21




Evaluated at index dateAge
Comorbidities
Heart failure
ICD-9 codes from discharge diagnosis database or codes from
exemptions from healthcare service co-payment database any





Hypertension ICD9-CM codes from discharge diagnosis database, or codes
from exemptions from healthcare service co-payment database
or the specific ATC codes from outpatient drug dispensing






ICD-9 codes from discharge diagnosis database or diabetologist
registry or codes from exemptions from healthcare service








ATC codes from outpatient drug dispensing within three









Available only for a subgroup of patients with data recorded in









Legend: COPD = chronic obstructive pulmonary disease; BMI = body mass index. a This category includes angina
pectoris, ischemic heart disease, acute myocardial infarction. b This category includes transient cerebral ischemia
and stroke. c This category includes vitamin K antagonists, heparins, thrombin direct inhibitors, factor Xa direct
inhibitors, fibrinolytic agents. d This category includes platelet aggregation inhibitors. e This category includes
Pregabalin, Gabapentin and Duloxetin.
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Figure A1. Prevalence (%) of AD users, stratified by calendar year and AD molecule/class.
Legend: AGI = alpha-glucosidase inhibitors; DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA =
glucagonlike peptide-1 receptor antagonists; SGLT2i = sodium–glucose linked transporter 2 inhibitors;
Other oral combinations = fixed-dose combinations of glitazones + DPP4i and glitazones + sulfonylureas.
Figure A2. Comparison between the mean body weight values (kg) at baseline and within
one year after ID, stratified by AD molecule/class. Legend: AGI = alpha-glucosidase inhibitors;
DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA = glucagonlike peptide-1 receptor antagonists;
SGLT2i = sodium–glucose linked transporter 2 inhibitors; Other oral combinations = fixed-dose
combinations of glitazones + DPP4i and glitazones + sulfonylureas; ID = index date. All incident AD
treatments with at least 12 months of follow-up were included.
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Figure A3. Comparison between the mean waist circumference values (cm) at baseline and within
one year after ID, stratified by AD molecule/class. Legend: AGI = alpha-glucosidase inhibitors;
DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA = glucagonlike peptide-1 receptor antagonists;
SGLT2i = sodium–glucose linked transporter 2 inhibitors; Other oral combinations = fixed-dose
combinations of glitazones + DPP4i and glitazones + Sulfonylureas; ID = index date. All incident AD
treatments with at least 12 months of follow-up were included.
Figure A4. Distribution (%) of continuers, add on, discontinuers and intermittent within
the first year of treatment among incident treatments, stratified by antidiabetic molecule/class.
Legend: AGI = alpha-glucosidase inhibitors; DPP4i = dipeptidyl peptidase-4 inhibitors; GLP-1RA =
glucagonlike peptide-1 receptor antagonists; SGLT2i = sodium–glucose linked transporter 2 inhibitors;
Other oral combinations = fixed-dose combinations of glitazones + DPP4i and glitazones + sulfonylureas.
All incident AD treatments with at least 12 months of follow-up were included.
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